hypervari
virus
adopt
sever
mechan
cope
host
humor
immun
respons
studi
mechan
accumul
point
mutat
immunodomin
region
surfac
protein
make
longer
recogniz
previous
gener
neutral
antibodi
nab
escap
mechan
involv
surfac
protein
includ
glycosyl
function
pivot
residu
glycan
shield
associ
host
serum
compon
eg
lipoprotein
order
mask
immun
system
figur
known
escap
mechan
sort
protect
rout
viru
spread
celltocel
transmiss
ii
molecular
mimicri
viral
protein
host
selfantigen
iii
stimul
subfamilyrestrict
antibodi
ab
obviou
implic
viralinduc
autoimmun
diseas
cryoglobulinemia
hcv
possibl
interf
effect
nonneutr
ab
nonnab
origin
propos
dulbecco
et
al
explain
appar
inhibit
viru
neutral
exert
serum
sampl
recent
propos
immun
escap
mechan
reacquir
relev
interest
especi
consid
potenti
clinic
use
neutral
antiinfecti
nab
design
vaccin
approach
date
two
main
mechan
propos
interf
effect
nonnab
direct
bind
interfer
steric
hindranc
ii
inhibit
bind
follow
conform
chang
viral
antigen
bound
interf
nonnabsmoreov
specul
even
directli
interf
nab
bind
nonnab
may
also
lead
enhanc
viral
infect
interact
fc
receptor
complement
receptor
overal
possibl
elicit
nonnab
infect
vaccin
individu
may
interfer
neutral
potenti
nab
detail
interf
ab
abl
bind
viral
protein
level
immunodomin
function
irrelev
region
viral
protein
decreas
block
bind
nab
crucial
viral
epitop
eg
receptorbind
domain
figur
candid
antivir
monoclon
antibodi
mab
polyclon
prepar
subject
mechan
interfer
escap
mechan
previous
mention
similarli
novel
vaccin
approach
avoid
elicit
interf
ab
could
even
worsen
diseas
case
real
infect
follow
paragraph
discuss
mechan
specif
exampl
role
cours
viral
infect
describ
hepat
c
viru
hcv
positivesens
singl
strand
rna
envelop
viru
caus
chronic
hepat
untreat
patient
consequ
risk
develop
cirrhosi
hepatocellular
carcinoma
million
peopl
world
popul
infect
worldwid
protect
vaccin
yet
avail
wherea
therapeut
option
still
limit
complet
effect
reason
chronic
hcv
infect
repres
major
indic
liver
transplant
europ
unit
state
moreov
transplant
recipi
subject
high
risk
graft
reinfect
sever
rapid
progress
liver
diseas
hcv
genom
encod
singl
polyprotein
aminoacid
process
host
viral
proteas
least
structur
core
nonstructur
protein
particular
envelop
type
membran
glycoprotein
form
noncoval
heterodim
surfac
hcv
envelop
allow
clathrinmedi
viru
endocytosi
interact
consecut
sever
entri
cellular
factor
glycosaminoglycan
lowdens
lipoprotein
receptor
scaveng
receptor
class
b
type
tetraspanin
tightjunct
protein
occludin
recent
describ
niemannpick
cholesterol
absorpt
receptor
develop
effect
prophylact
therapeut
approach
viru
hinder
mainli
high
mutat
rate
give
rise
highli
diversifi
viral
variant
even
within
singl
patient
quasispeci
inde
seven
major
genotyp
vari
nucleotid
sequenc
sever
subtyp
recogn
character
differ
clinic
featur
differ
evolutionari
rate
chronic
liver
diseas
differ
respons
avail
antivir
therapi
develop
use
antihcv
mab
capabl
target
structur
function
conserv
region
highli
variabl
viral
particl
consid
novel
therapeut
tool
particular
product
potent
nab
acut
infect
shown
correl
viral
clearanc
singlesourc
outbreak
cohort
moreov
vaccin
chimpanze
sustain
ab
respons
envelop
glycoprotein
correl
reduc
viremia
passiv
administr
neutral
mab
upascid
chimer
mous
model
infect
abl
protect
challeng
hcv
quasispeci
inoculum
broadli
human
mab
direct
surfac
glycoprotein
hcv
typic
direct
function
import
region
within
bind
site
well
critic
residu
highli
conserv
among
differ
genotyp
aspect
crucial
possibl
therapeut
vivo
use
mab
may
suffici
sinc
recent
suppos
nonnab
popul
may
interfer
neutral
activ
fact
persist
infect
individu
crossnab
gener
elicit
low
titer
late
stage
infect
lead
poor
control
viremia
wherea
quasispeciesspecif
neutral
high
titer
nonnab
elicit
earlier
moreov
vivo
use
antihcv
polyclon
immunoglobulin
prepar
chimpanze
human
disappoint
clinic
studi
shown
prepar
fail
prevent
recurr
infect
patient
liver
transplant
regard
recent
paper
suggest
effect
nab
direct
function
import
residu
involv
viral
bind
within
epitop
encompass
aminoacid
residu
could
hinder
presenc
nonnab
bind
residu
within
epitop
ii
aminoacid
residu
particular
block
interf
epitop
iispecif
ab
rais
neutral
titer
serum
contain
epitop
epitop
iispecif
ab
also
uncov
broader
crossgenotyp
neutral
respons
howev
role
exist
interf
ab
influenc
hcv
infect
still
controversi
author
recent
corrobor
data
zhang
et
al
vitro
neutral
assay
use
serumderiv
hcv
genotyp
polyclon
ab
deriv
immun
goat
differ
conserv
peptid
span
aminoacid
residu
glycoprotein
particular
group
found
interf
activ
exert
weakli
neutral
ab
neutral
activ
ab
interestingli
accord
put
model
fold
three
aforement
region
would
lie
next
glycoprotein
therefor
structur
predict
possibl
support
interf
effect
epitop
iidirect
ab
howev
predict
structur
current
best
model
avail
conclus
absolut
ascertain
purpos
avail
crystal
certainli
acceler
fine
elucid
spatial
proxim
neutral
interf
mab
structur
consequ
structurebas
vaccin
progress
moreov
noteworthi
individu
ab
target
region
encompass
epitop
frequent
harbor
ab
recogn
region
contain
epitop
ii
thu
confirm
epitop
final
shown
low
preval
less
low
titer
epitop
ireact
ab
sera
chronic
acut
resolv
infect
thu
support
hypothesi
conform
mask
adjac
region
contain
epitop
ii
fact
zhang
et
al
origin
put
forward
idea
epitop
ii
bound
ab
site
epitop
becom
mask
longer
recogn
specif
nab
inde
deplet
ab
epitop
ii
plasma
chronic
infect
hcv
patient
vaccin
chimpanze
recov
otherwis
undetect
crossgenotyp
neutral
activ
anoth
possibl
initi
bind
interf
ab
region
contain
epitop
ii
may
induc
conform
chang
inhibit
bind
epitop
idirect
ab
recent
suggest
lapierr
et
al
ab
convers
conclus
support
recent
studi
tarr
et
al
use
murin
rat
mab
well
human
immunoglobulin
fraction
affinitypurifi
linear
peptid
repres
distinct
domain
cluster
within
region
although
confirm
previous
report
coimmunogen
two
region
author
fail
demonstr
inhibit
two
group
ab
consid
result
author
inde
suggest
interfer
nonnab
least
region
encompass
residu
possibl
mechan
hcv
persist
chronic
infect
individu
origin
propos
zhang
et
al
accord
find
tarr
colleagu
keck
et
al
describ
human
mab
bind
conformationsensit
epitop
encompass
also
residu
within
interf
region
mab
broadli
neutral
lead
viral
escap
mutant
demonstr
function
import
epitop
author
conclud
ab
direct
epitop
ii
interf
also
specul
interf
activ
could
limit
ab
recogn
linear
epitop
within
recent
partli
confirm
observ
zhang
et
al
use
panel
mab
well
character
mous
mab
whose
epitop
encompass
epitop
aminoacid
residu
weakli
neutral
human
mab
name
whose
epitop
encompass
epitop
ii
particular
found
abl
interfer
neutral
activ
genotyp
viru
strain
instead
found
minim
interfer
activ
two
broadli
crossneutr
human
mab
name
interestingli
found
bind
also
residu
within
epitop
ii
higher
affin
compar
thu
displac
interf
epitop
therefor
keep
unalt
neutral
activ
thu
opinion
describ
diverg
observ
report
may
depend
differ
ab
specif
present
polyclon
prepar
use
probabl
also
differ
hcv
genotyp
infect
studi
patient
moreov
differ
strategi
adopt
isol
epitop
epitop
iidirect
ab
follow
studi
could
explain
differ
data
obtain
fact
immunoglobulin
purifi
peptid
repres
distinct
region
obvious
direct
linear
epitop
prepar
certainli
differ
mab
clone
use
fulllength
glycoprotein
probabl
direct
conform
epitop
includ
also
residu
outsid
investig
linear
region
summar
hcv
field
sever
work
support
exist
interf
ab
popul
hypothes
possibl
role
hcv
persist
demonstr
use
human
plasmaderiv
immunoglobulin
prepar
human
mab
sera
anim
vaccin
recombin
peptid
possibl
mechan
lead
interfer
still
controversi
direct
steric
hindranc
induc
antigen
conform
chang
hypothes
hand
paper
confirm
find
suggest
put
interf
epitop
ii
may
target
ab
endow
broadli
neutral
activ
recent
paper
use
well
character
mab
show
interf
ab
exist
overal
effect
may
bias
presenc
nab
differ
bind
featur
infect
hcv
genotyp
futur
work
investig
vivo
role
interf
ab
subpopul
hcv
persist
certainli
use
influenza
virus
circul
worldwid
anim
reservoir
especi
water
fowl
potenti
affect
human
age
group
influenza
virus
classifi
type
b
c
base
antigen
differ
nucleoprotein
matrix
protein
clinic
relev
variabl
type
influenza
divid
sever
subtyp
accord
antigen
characterist
two
envelop
glycoprotein
caus
epidem
pandem
infect
yearli
recur
influenza
epidem
associ
signific
morbid
mortal
particularli
among
risk
group
elderli
peopl
chronic
medic
condit
pregnant
women
children
global
spread
pandem
influenza
virus
caus
million
death
within
envelop
influenza
virion
eight
segment
neg
singlestrand
rna
protect
nucleocapsid
protein
form
ribonucleoprotein
rnp
first
six
rna
segment
code
singl
protein
pa
constitut
rnadepend
rna
polymeras
hemagglutinin
ha
nucleoprotein
np
neuraminidas
na
last
two
segment
code
two
differ
protein
matrix
protein
nonstructur
protein
three
differ
protein
ha
na
present
viral
envelop
ha
glycoprotein
abund
major
target
humor
immun
respons
togeth
na
transmembran
glycoprotein
ha
capabl
elicit
subtypespecif
immun
respons
fulli
protect
within
partial
protect
across
differ
subtyp
ha
synthes
inact
precursor
transit
activ
form
upon
cleavag
host
cell
proteas
present
viral
membran
homotrim
ha
trimer
bind
sialic
acid
molecul
cell
membran
protein
lipid
domain
locat
globular
head
monom
subsequ
viral
envelop
fuse
clathrindepend
independ
mechan
endocyt
vesicl
membran
ha
fusion
peptid
locat
stem
region
monom
consequ
viral
compon
releas
host
cell
subvert
synthet
capabl
host
cell
product
releas
progeni
particl
humor
immun
play
import
role
host
defens
influenza
viru
infect
ab
neutral
influenza
virus
henc
limit
infect
fact
larg
bodi
experiment
work
suggest
occlus
receptorbind
site
ha
ab
main
mechan
influenza
viral
neutral
less
common
broadli
nab
may
neutral
influenza
viru
inhibit
fusion
viral
envelop
endocyticvesicl
membran
aminoacid
chang
ha
frequent
immunodomin
globular
head
complex
effect
viral
neutral
ab
usual
allow
mutat
variant
escap
previous
gener
nab
classic
studi
use
neutral
mous
mab
identifi
five
distinct
antigen
site
globular
head
region
threedimension
structur
ha
molecul
ahong
well
subtyp
first
day
infect
nab
titer
often
low
titer
nonnab
higher
may
play
role
outcom
infect
recent
observ
influenza
pandem
viru
infect
patient
et
al
particular
group
found
amount
well
avid
nonnab
higher
patient
sever
diseas
mild
diseas
author
conclud
exagger
nonnab
respons
earli
stage
infect
associ
sever
diseas
moreov
author
specul
nonnab
present
patient
sera
earli
stage
infect
like
either
preexist
result
secondari
heterosubtyp
humor
immun
respons
conserv
epitop
sever
influenza
protein
earli
humor
respons
elicit
within
day
infect
immun
prime
previou
exposur
share
viral
epitop
fact
matrix
protein
nucleoprotein
conserv
aminoacid
sequenc
therefor
ab
protein
previou
season
influenza
viru
infect
vaccin
could
induc
inde
upon
infect
influenza
viru
memori
bcell
prolifer
rapidli
gener
larg
amount
high
avid
nonnab
especi
patient
sever
diseas
consist
observ
number
peripher
blood
bcell
higher
patient
sever
diseas
mild
diseas
earli
stage
infect
mechan
ab
neutral
interfer
indirectli
specul
also
ndifon
et
al
observ
aminoacid
chang
ha
actual
increas
effici
neutral
escap
variant
previous
gener
ab
even
directli
influenc
bind
detail
group
suggest
increas
neutral
activ
ha
mutat
could
result
lesser
steric
interfer
ab
specif
steric
competit
bind
ha
ab
differ
neutral
effici
mutat
reduc
bind
ab
low
neutral
activ
could
increas
overal
viral
neutral
inde
similarli
specul
hcv
ab
bind
ha
epitop
locat
distanc
receptorbind
site
may
therefor
fail
occupi
site
effici
therebi
lead
decreas
viral
neutral
moreov
shown
ab
bind
certain
ha
epitop
prevent
bind
ab
epitop
ha
protein
even
epitop
found
adjac
ha
protein
observ
suggest
ab
bind
lowneutr
effici
epitop
ha
might
interfer
bind
nab
close
effici
epitop
therebi
imped
neutral
influenza
virus
consid
ha
structur
bind
interf
ab
would
lie
level
epitop
c
e
locat
far
receptorbind
site
globular
head
ha
howev
bind
ab
may
influenc
bind
nab
epitop
b
locat
closer
receptorbind
site
regard
chang
epitop
b
could
highli
favor
natur
select
wherea
chang
epitop
c
e
could
disadvantag
influenza
virus
similarli
hcv
sounder
confirm
due
avail
crystal
structur
specul
rais
intrigu
possibl
influenza
virus
may
evolv
favor
preferenti
elicit
ab
recogn
epitop
lowneutr
profil
inde
steric
hindranc
ab
bind
epitop
could
greatli
reduc
extent
mutat
requir
viru
evad
neutral
host
ab
consequ
decreas
affin
ab
epitop
lowneutr
effici
could
lead
increas
viral
neutral
suggest
possibl
approach
design
lowinterfer
vaccin
could
greatli
diminish
impact
ab
interfer
immunogen
genet
modifi
viral
target
level
effici
epitop
inde
vaccineinduc
ab
recogn
highneutr
effici
epitop
target
ab
induc
lowinterfer
vaccin
strain
low
affin
lowneutr
effici
epitop
target
circul
viru
strain
therefor
interfer
ab
highneutr
effici
epitop
impli
improv
neutral
consequ
limit
abmedi
interfer
target
viru
escap
vaccineinduc
ab
small
epitop
chang
altern
vaccin
could
design
includ
region
correspond
epitop
highneutr
effici
furthermor
antivir
drug
could
design
includ
viral
protein
carri
modif
level
highneutr
effici
epitop
decoy
protein
would
compet
viru
bind
lowneutr
effici
ab
manner
similar
play
neuraminidas
inhibitor
synthesi
avail
ha
crystal
structur
help
confirm
exist
explain
mechan
interfer
non
weaklyneutr
antiha
ab
recent
work
et
al
evidenc
nonnab
respons
earli
stage
infect
associ
sever
diseas
may
first
proof
role
interf
ab
cours
natur
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
posit
singlestrand
rna
viru
emerg
guangdong
peopl
republ
china
spread
countri
infect
control
effort
brought
infect
control
case
includ
almost
death
report
outbreak
period
increas
age
comorbid
risk
factor
sever
diseas
death
sinc
sporad
case
report
howev
possibl
sar
outbreak
could
reemerg
natur
deliber
releas
public
health
concern
like
influenza
virus
sarscov
circul
anim
reservoir
bat
thought
transmit
viru
small
mammal
exposur
small
anim
sourc
human
infect
clinic
diseas
similar
sever
acut
respiratori
infect
includ
influenza
sar
case
definit
includ
clinic
epidemiolog
laboratori
criteria
basic
genom
organ
replic
cycl
similar
cov
gene
encod
predict
replicasetranscriptas
protein
translat
input
genom
rna
gene
encod
structur
accessori
protein
includ
envelop
spike
protein
translat
separ
subgenom
mrna
cov
use
uniqu
discontinu
mechan
transcrib
seri
progress
larger
subgenom
mrna
contain
leader
rna
sequenc
deriv
end
genom
protein
cov
insert
envelop
virion
mediat
bind
fusion
event
necessari
infect
major
target
humor
protect
immun
although
protein
sarscov
sarss
share
littl
aminoacid
ident
approxim
share
common
structur
featur
protein
member
coronavirida
famili
sarss
protein
type
transmembran
glycoprotein
approxim
amino
acid
length
divid
two
function
domain
aminoacid
residu
aminoacid
residu
mani
cov
protein
cleav
biogenesi
two
function
domain
held
togeth
noncoval
howev
case
human
cov
protein
cleav
sarscov
domain
form
globular
structur
mediat
interact
protein
main
receptor
angiotensinconvert
enzym
domain
mediat
fusion
contain
put
fusion
peptid
two
conserv
helic
region
upon
cleavag
endosom
proteas
cathepsin
l
form
six
helix
bundl
fusion
core
vaccin
strategi
aim
blockinglimit
infect
sarscov
mainli
focu
target
sarss
viral
glycoprotein
nonetheless
strategi
pose
singular
dilemma
cov
previou
vaccin
protocol
highlight
possibl
immunemedi
enhanc
diseas
regard
group
zhong
et
al
investig
role
nonneutr
interf
ab
also
case
sarscov
infect
particular
found
two
mab
direct
region
encompass
aminoacid
residu
sarss
act
synergist
inhibit
sarscov
infect
vitro
nonneutr
mab
whose
epitop
encompass
mention
region
disrupt
neutral
activ
analyz
crystal
structur
sarss
protein
author
propos
possibl
explan
observ
evidenc
epitop
mab
close
pack
proxim
distal
receptor
bind
site
moreov
epitop
nonneutr
mab
partial
overlap
least
aminoacid
neutral
mab
consequ
mab
could
inhibit
mab
bind
equilibriumrel
manner
hand
author
found
mab
could
steric
interfer
bind
mab
propos
mechan
spatial
occup
figur
fact
access
mab
epitop
may
block
mab
bind
mask
surfac
area
contain
fact
specul
davi
cohen
buri
area
ab
rang
correspond
aminoacid
although
aminoacid
residu
real
epitop
make
direct
contact
ab
fact
previous
observ
hcv
influenza
human
anim
virus
one
possibl
mechan
steric
block
nonnab
reduc
bind
nab
sarss
protein
disabl
neutral
convers
notwithstand
epitop
mab
locat
singl
loop
spatial
separ
therebi
provid
distinct
interfac
independ
ab
bind
conclud
sarscov
elicit
potenti
interf
nonnab
present
surfac
close
pack
region
differ
biolog
featur
hand
host
mount
vigor
neutral
humor
respons
produc
ab
recogn
distinct
epitop
act
synergist
particular
result
suggest
cocktail
neutral
human
mab
bind
uniqu
epitop
differ
mechan
action
might
clinic
util
sarscov
infect
indic
similar
approach
may
appli
treat
viral
infect
human
immunodefici
viru
hiv
posit
singlestrand
rna
retroviru
caus
substanti
morbid
mortal
across
globe
particularli
develop
countri
human
immunodefici
virus
type
result
multiinterspeci
transmiss
simian
viru
human
preval
low
higher
proport
infect
individu
progress
acquir
immunodefici
diseas
syndrom
aid
compar
infect
virus
diverg
classifi
four
group
n
p
particular
group
subdivid
nine
subtyp
numer
circul
recombin
form
genom
retrovirus
encod
gag
pol
env
structur
protein
among
hiv
structur
protein
surfac
envelop
glycoprotein
form
heterodim
organ
trimer
surfac
viral
membran
entri
target
cell
initi
interact
surfac
envelop
glycoprotein
coreceptor
typic
target
cell
portion
bind
target
cell
receptor
promot
fusion
viral
cellular
membran
upon
bind
receptor
undergo
conform
chang
result
exposur
epitop
bound
coreceptor
molecul
eventu
format
transient
prehairpin
intermedi
conform
prehairpin
intermedi
molecul
reorgan
ntermin
peptid
form
trimer
helic
expos
fusion
peptid
target
cell
ctermin
helic
remain
anchor
viral
membran
stage
vulner
number
nab
peptid
capabl
bind
either
n
ctermin
peptid
upon
fusion
target
cell
membran
reorgan
result
associ
n
ctermin
peptid
creat
sixhelix
postfus
bundl
fusion
deliveri
viral
capsid
cytoplasm
uncoat
lead
releas
viral
enzym
protein
genom
rna
insid
cell
revers
transcript
viral
genom
singlestrand
posit
rna
initi
yield
doublestrand
provir
dna
import
nucleu
integr
host
chromosom
activ
transcript
integr
provir
dna
occur
presenc
viral
tat
splice
viral
mrna
yield
earli
accessori
protein
like
tat
rev
nef
help
transcript
splice
modif
cellular
machineri
respect
accumul
rev
protect
viral
mrna
splice
thu
yield
increasingli
longer
mrna
abl
code
structur
envelop
protein
final
viral
genom
rna
readi
encapsid
antiretrovir
drug
therapi
hiv
highli
effect
control
infect
howev
erad
viru
current
practic
treatment
therefor
lifelong
burden
consider
toxic
drug
resist
vaccin
wide
view
crucial
control
epidem
sever
advanc
effort
develop
effect
prophylaxi
result
unsuccess
one
greatest
challeng
develop
vaccin
hiv
overcom
abil
constantli
mutat
escap
antihiv
immun
respons
high
mutat
rate
direct
result
presenc
viru
low
fidel
rna
polymeras
well
high
level
recombin
undergo
constantli
evolv
glycan
shield
envelop
glycoprotein
regard
cytotox
lymphocyt
nab
long
report
select
immun
escap
variant
cours
infect
candid
passiv
immunotherapi
could
consist
previous
suggest
sarscov
infect
administr
cocktail
broadli
neutral
mab
could
minim
onset
viral
escap
mutant
variou
combin
human
mab
studi
past
sever
year
shown
addit
synergist
antagonist
effect
neutral
antagonist
effect
neutral
previous
report
pair
mab
direct
bind
site
respect
molecular
mechan
determin
antagon
studi
detail
studi
describ
first
time
molecular
level
possibl
mechan
interfer
also
hiv
perform
use
pair
combin
mab
detail
author
note
antagonist
effect
neutral
mab
combin
nonneutr
mab
particular
mab
recogn
differ
epitop
locat
within
cluster
aminoacid
residu
cluster
ii
aminoacid
residu
respect
hand
mab
recogn
differ
epitop
mab
within
membraneproxim
extern
region
mper
portion
adjac
cluster
ii
region
moreov
overlap
cluster
ii
epitop
epitop
recogn
mab
explain
inhibit
mab
bind
mab
thu
case
antagon
mab
author
hypothes
mechan
steric
hindranc
two
mab
could
bind
peptid
peptid
complex
repres
prefusogen
fusogen
form
particular
mab
higher
affin
peptid
complex
repres
fusogen
form
thu
bind
fail
neutral
isol
could
interfer
bind
lead
neutral
antagon
contrast
mab
recogn
distinct
epitop
display
independ
addit
reactiv
combin
mab
test
conclud
ab
induc
individu
predominantli
nonneutr
sinc
function
import
region
hiv
surfac
protein
almost
complet
hidden
immun
system
intrigu
hypothesi
togeth
hiv
escap
mechan
effect
extrem
rare
nab
may
also
hinder
overwhelm
amount
interf
nonnab
date
exist
interf
nonnab
clearli
evidenc
use
mab
differ
biolog
featur
wherea
data
gener
use
mab
possibl
role
nonnabmedi
interfer
facilit
hiv
escap
cours
natur
infect
certainli
deserv
futur
studi
immunoprophylact
immunotherapeut
approach
mab
still
consid
possibl
support
tool
manag
infecti
diseas
particular
avail
broadli
neutral
mab
direct
viral
pathogen
whose
actual
prophylact
therapeut
approach
far
effect
led
mani
ongo
clinic
trial
howev
evid
report
review
suggest
candid
mab
possibl
use
antivir
passiv
immun
approach
elicit
futur
vaccin
strategi
highli
crossneutr
molecul
also
tailor
molecul
whose
activ
influenc
possibl
interf
ab
produc
cours
infect
end
must
either
direct
highli
neutral
epitop
subject
mechan
interfer
must
featur
high
affin
antigen
order
displac
bind
possibl
interf
ab
